Biogen Inc. has announced significant changes in its executive team through a recent Form 8-K filing with the SEC. Effective March 1, 2025, Sean Godbout will be appointed as the Vice President, Chief Accounting Officer, and Global Corporate Controller. Concurrently, he will assume the role of the company's principal accounting officer, succeeding Robin Kramer who has been appointed as Biogen's Chief Financial Officer following the retirement of Michael McDonnell on the same date.

Sean Godbout, who has been with Biogen since 2007 and served as Global Corporate Controller since October 2023, brings extensive experience to his new role. Prior to joining Biogen, he held positions at PricewaterhouseCoopers LLP. He holds a B.S. from Cornell University and an M.S. in Accounting and MBA from Northeastern University. Mr. Godbout is also a Certified Public Accountant in Massachusetts.

As part of his compensation, Mr. Godbout will have a base salary of $400,000, with eligibility for an annual bonus targeted at 40% of his base salary. His long-term incentive grant for 2025 will align with the company's LTI plans and guidelines at the time of the grant. Additionally, under Biogen's executive severance plan for Vice Presidents, Mr. Godbout will be entitled to severance benefits including a lump sum payment in certain termination scenarios and continued medical and dental insurance benefits if applicable.

These executive transitions are part of Biogen's strategic leadership adjustments aimed at sustaining its growth and operational efficiency.